Metabolism of MPTP by cytochrome P4502D6 and the demonstration of 2D6 mRNA in human foetal and adult brain by in situ hybridization.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Xenobiotica; the fate of foreign compounds in biological systems

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1080/004982597240802PMID 9041683
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4--implications for susceptibility to Parkinson's disease.

  1996cited by this paper
• Analysis of foetal expression sites of human type II DNA topoisomerase alpha and beta mRNAs by in situ hybridisation.

  1996cited by this paper
• Functional high level expression of cytochrome P450 CYP2D6 using baculoviral expression systems.

  1996cited by this paper
• A model for human cytochrome P450 2D6 based on homology modeling and NMR studies of substrate binding.

  1996cited by this paper
• Parkinson's disease epidemiology in the Northampton District, England, 1992

  1995cited by this paper
• Clinical implications of genetic polymorphism in drug metabolism.

  1994cited by this paper
• pNAT and CYP2D6 gene polymorphism in epileptic patients.

  1994cited by this paper
• Are poor metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers?

  1993cited by this paper
• Metabolic aspects of the behavior of MPTP and some analogues.

  1993cited by this paper
• Neurologic diseases associated with use of plant components with toxic potential.

  1993cited by this paper
• Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease.

  1992cited by this paper
• Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics.

  1992cited by this paper
• Protection and potentiation of MPTP-induced toxicity by cytochrome P-450 inhibitors and inducer: in vitro studies with brain slices.

  1991cited by this paper
• Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6.

  1991cited by this paper
• MPTP-induced ATP depletion and cell death in neuroblastoma X glioma hybrid NG 108-15 cells: protection by glucose and sensitization by tetraphenylborate.

  1991cited by this paper
• Acute Effects of 1‐Methyl‐4‐Phenyl‐1, 2, 3, 6‐Tetrahydropyridine in a Model of Rat Designated a Poor Metabolizer of Debrisoquine

  1991cited by this paper
• Abnormal liver enzyme‐mediated metabolism in Parkinson's disease

  1991cited by this paper
• Metabolic factors in cancer susceptibility.

  1990cited by this paper
• The dopamine transporter and cytochrome P45OIID1 (debrisoquine 4-hydroxylase) in brain: resolution and identification of two distinct [3H]GBR-12935 binding proteins.

  1990cited by this paper
• Metabolic factors in cancer susceptibility.

  1990cited by this paper
• Parkinson's disease and cytochrome P450: a possible link?

  1990cited by this paper
• Identification of the primary gene defect at the cytochrome P450 CYP2D locus

  1990cited by this paper
• Molecular mechanisms of drug resistance.

  1990cited by this paper
• Debrisoquine hydroxylation polymorphism and personality.

  1989cited by this paper
• The localization of laminin mRNA and protein in the postimplantation embryo and placenta of the mouse: an in situ hybridization and immunocytochemical study.

  1988cited by this paper
• Chemical oxidation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its in vivo metabolism in rat brain and liver.

  1988cited by this paper
• Characterization of the common genetic defect in humans deficient in debrisoquine metabolism

  1988cited by this paper
• Characterization of hepatic microsomal metabolism as an in vivo detoxication pathway of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.

  1988cited by this paper
• Cation-exchange high-performance liquid chromatography assay for the nigrostriatal toxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and its monoamine oxidase B generated metabolites in brain tissues.

  1987cited by this paper
• High-performance liquid chromatographic assays for bufuralol 1'-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver.

  1987cited by this paper
• Debrisoquine metabolism in parkinsonian patients treated with antihistamine drugs.

  1987cited by this paper
• MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylation.

  1987cited by this paper
• Contribution of N-oxygenation to the metabolism of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) by various liver preparations.

  1986cited by this paper
• Debrisoquine/sparteine-type polymorphism of drug oxidation. Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol.

  1986cited by this paper
• Metabolism of the nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by liver homogenate fractions.

  1985cited by this paper
• Permanent human parkinsonism due to 1‐methy 1–4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)

  1985cited by this paper
• Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine.

  1985cited by this paper
• Oxidation of the neurotoxic amine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by monoamine oxidases A and B and suicide inactivation of the enzymes by MPTP.

  1984cited by this paper
• Presence of NADPH-cytochrome P450 reductase in central catecholaminergic neurones

  1984cited by this paper
• A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

  1980cited by this paper
• [4] Isolation and use of liver cells

  1978cited by this paper
• Protein measurement with the Folin phenol reagent.

  1951cited by this paper

• CNS Viral Infections—What to Consider for Improving Drug Treatment: A Plea for Using Mathematical Modeling Approaches

  2024cites this paper
• Cytochrome P450 enzymes and metabolism of drugs and neurotoxins within the mammalian brain.

  2022cites this paper
• Contribution of CYP2D6 Functional Activity to Oxycodone Efficacy in Pain Management: Genetic Polymorphisms, Phenoconversion, and Tissue-Selective Metabolism

  2021cites this paper
• Cytochrome P450 expression and regulation in the brain

  2020cites this paper
• Characterization of CYP2D protein from human brain cerebellum

  2020cites this paper
• Mitochondrially targeted cytochrome P450 2D6 is involved in monomethylamine-induced neuronal damage in mouse models

  2019cites this paper
• Pharmacogenetics of neurological and psychiatric diseases at older age: has the time come?

  2017cites this paper
• The Effect of Altering Brain CYP2B Activity on Nicotine Self-administration Behaviour and Nicotine Levels in the Brain

  2016cites this paper
• Emerging roles for brain drug-metabolizing cytochrome P450 enzymes in neuropsychiatric conditions and responses to drugs

  2016cites this paper
• In situ hybridization study of CYP2D mRNA in the common marmoset brain

  2016cites this paper
• The pharmacogenetic road to avoid adverse drug reactions and therapeutic failures in revolving door patients with psychiatric illnesses: focus on the CYP2D6 isoenzymes

  2016cites this paper
• Detoxification of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by cytochrome P450 enzymes: A theoretical investigation.

  2016cites this paper
• Psychiatry meets pharmacogenetics for the treatment of revolving door patients with psychiatric disorders

  2016cites this paper
• Computational predictions of the site of metabolism of cytochrome P450 2D6 substrates: comparative analysis, molecular docking, bioactivation and toxicological implications

  2015cites this paper
• Polymorphism in CYP2D6 and CYP2C19, members of the cytochrome P450 mixed‐function oxidase system, in the metabolism of psychotropic drugs

  2015cites this paper
• CYP2D6 phenotypes and Parkinson's disease risk: a meta-analysis.

  2014cites this paper
• Quantitative assessment of CYP2D6 polymorphisms and risk of Alzheimer's disease: a meta-analysis.

  2014cites this paper
• Ethanol self‐administration and nicotine treatment increase brain levels of CYP2D in African green monkeys

  2014influential citation
• Drug Response Heterogeneity and the Genetic Variability of Cytochrome P450–Metabolizing Enzymes

  2014cites this paper
• CYP2D6 variation, behaviour and psychopathology: implications for pharmacogenomics-guided clinical trials.

  2014cites this paper
• Acetaldehyde and parkinsonism: role of CYP450 2E1

  2013cites this paper
• Metabolite Profile Resulting from the Activation/Inactivation of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 2-Methyltetrahydro-β-carboline by Oxidative Enzymes

  2013influential citation
• Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function

  2013cites this paper
• The Expression and Regulation of CYP2D in a Monkey Model of Ethanol and Nicotine Exposure

  2013cites this paper
• The Association Study of Polymorphisms in DAT, DRD2, and COMT Genes and Acute Extrapyramidal Adverse Effects in Male Schizophrenic Patients Treated With Haloperidol

  2013cites this paper
• Ontogeny of mammalian metabolizing enzymes in humans and animals used in toxicological studies

  2012cites this paper
• 1‐Methyl‐4‐phenyl‐1,2,5,6‐Tetrahydropyridine (MPTP)

  2012cites this paper
• Metabolism of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine by Mitochondrion-targeted Cytochrome P450 2D6

  2012cites this paper
• Two Faces of 1,2,3,4-Tetrahydroisoquinoline Mode of Action in the Mammalian Brain: Is It an Endogenous Neurotoxin or a Neuromodulator?

  2012cites this paper
• Pesticide exposure and Parkinson's disease: epidemiological evidence of association.

  2012cites this paper
• Inhibition of Brain CYP2D Lowers Codeine-induced Analgesia in Rats

  2012cites this paper
• Blood-brain barrier P450 enzymes and multidrug transporters in drug resistance: a synergistic role in neurological diseases.

  2011cites this paper
• Cytochrome P450 2D6 enzyme neuroprotects against 1‐methyl‐4‐phenylpyridinium toxicity in SH‐SY5Y neuronal cells

  2010cites this paper
• Pharmacogenomics and Personality: Role of CYP2D6 and Implications for Psychopathology

  2010cites this paper
• ABC transporters and cytochromes P450 in the human central nervous system: influence on brain pharmacokinetics and contribution to neurodegenerative disorders

  2010influential citation
• Ontogeny of hepatic drug metabolizing enzymes in sheep

  2010cites this paper
• Substrate specificity, inhibitors and regulation of human cytochrome P450 2D6 and implications in drug development.

  2009cites this paper
• Microsoft Word-2605495-file00

  2009cites this paper
• The Influence of Genetic Polymorphisms on Population Variability in Six Xenobiotic-Metabolizing Enzymes

  2009cites this paper
• Xenobiotic-Metabolizing Enzymes and Transporters in the Normal Human Brain: Regional and Cellular Mapping as a Basis for Putative Roles in Cerebral Function

  2009cites this paper
• Polymorphism of human cytochrome P450 enzymes and its clinical impact

  2009cites this paper
• Genetic Polymorphism in Cytochrome P450 2D6 (CYP2D6): Population Distribution of CYP2D6 Activity

  2009influential citation
• Brain Drug-Metabolizing Cytochrome P450 Enzymes are Active In Vivo, Demonstrated by Mechanism-Based Enzyme Inhibition

  2009cites this paper
• Study on herb-drug interactions

  2009cites this paper
• New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme

  2009cites this paper
• CYTOCHROME P 450 2 E 1 – RELEVANCE FOR CENTRAL DOPAMINE NEUROTRANSMISSION AND PARKINSON ’ S DISEASE

  2008cites this paper
• CYTOCHROME P450 2E1 - RELEVANCE FOR CENTRAL DOPAMINE NEUROTRANSMISSION AND PARKINSON'S DISEASE

  2008cites this paper
• Xenobiotic metabolizing enzymes in the central nervous system: Contribution of cytochrome P450 enzymes in normal and pathological human brain.

  2008cites this paper
• Einfluss des Cytochrom P450 Enzyms CYP2D6 auf den Metabolismus von Methadon

  2008cites this paper
• Nicotine and caffeine-mediated modulation in the expression of toxicant responsive genes and vesicular monoamine transporter-2 in 1-methyl 4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease phenotype in mouse.

  2008cites this paper
• Chronic nicotine treatment induces rat CYP2D in the brain but not in the liver: an investigation of induction and time course.

  2008cites this paper
• Cytochrome P450 Reactions in the Human Brain

  2007cites this paper
• Amine oxidases and monooxygenases in the in vivo metabolism of xenobiotic amines in humans: has the involvement of amine oxidases been neglected?

  2007cites this paper
• Polymorphisms in the genes of citohrom oxidase P450 2D6 (CYP2D6), paraoxonase 1 (PON1) and apolipoproteine E (APOE) as risk factors for Parkinson's disease

  2007cites this paper
• N-methyltetrahydro-beta-carboline analogs of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin are oxidized to neurotoxic beta-carbolinium cations by heme peroxidases.

  2007cites this paper
• Cytochrome P450-catalyzed pathways in human brain: metabolism meets pharmacology or old drugs with new mechanism of action?

  2007cites this paper
• [Polymorphisms in the genes of cytochrome oxidase P450 2D6 (CYP2D6), paraoxonase 1 (PON1) and apolipoprotein E (APOE) as risk factors for Parkinson's disease].

  2007cites this paper
• Comparative aromatic hydroxylation and N-demethylation of MPTP neurotoxin and its analogs, N-methylated beta-carboline and isoquinoline alkaloids, by human cytochrome P450 2D6.

  2006cites this paper
• EXPRESSION, PURIFICATION, AND CHARACTERIZATION OF MOUSE CYP2D22

  2006influential citation
• EXPRESSION , PURIFICATION , AND CHARACTERIZATION OF MOUSE CYP 2 D 22

  2006influential citation
• Cytochrome P450 and xenobiotic receptor humanized mice.

  2006cites this paper
• Environmental genotoxicants/carcinogens and childhood cancer: bridgeable gaps in scientific knowledge.

  2006cites this paper
• Association of CYP2D6 genotypes and personality traits in healthy individuals.

  2006cites this paper
• Olanzapine-induced oculogyric crisis.

  2006cites this paper
• CYP: cytochrome P450; HT: hexahistidine-tagged; ES/LC-MS: electrospray ionization/liquid chromatography mass spectrometry; PMSF: phenylmethylsulfonyl fluoride; CHAPS: 3-[(3-cholamidopropyl)dimethyl-ammonio]-1-propanesulfonate; EDDP: 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine; TFA: trifluoroac

  2006influential citation
• Liver enzyme induction and inhibition: implications for anaesthesia

  2006cites this paper
• Inhibition of rat liver CYP2D in vitro and after 1-day and long-term exposure to neuroleptics in vivo-possible involvement of different mechanisms.

  2005cites this paper
• Case-only study of interactions between specific genetic polymorphisms and cigarette smoking in the aetiology of Parkinson's disease

  2005influential citation
• Severe adverse effects in a newborn with two defective CYP2D6 alleles after exposure to paroxetine during late pregnancy.

  2004cites this paper
• Interaction between GSTM1‐null and CYP2D6‐deficient alleles in the pathogenesis of Parkinson's disease

  2004cites this paper
• Polymorphic Cytochrome P450 2D6: Humanized Mouse Model and Endogenous Substrates

  2004influential citation
• Genetic polymorphism of CYP2D6 in patients with cardiovascular disease – a cohort study

  2004cites this paper
• Association between cytochrome P450 2D6 genotype and harm avoidance

  2004cites this paper
• The neurotoxicology of hard foraging and fat-melts

  2004cites this paper
• CYP2D6 polymorphism, pesticide exposure, and Parkinson's disease

  2004influential citation
• Drug-Metabolizing Enzymes and P-Glycoprotein

  2004cites this paper
• Disposition of 1,2,3,4,-tetrahydroisoquinoline in the brain of male Wistar and Dark Agouti rats.

  2004cites this paper
• The Unique Regulation of Brain Cytochrome P450 2 (CYP2) Family Enzymes by Drugs and Genetics

  2004influential citation
• Pesticides and pesticide combinations on brain neurochemistry

  2004influential citation
• Potential Role of Cerebral Cytochrome P450 in Clinical Pharmacokinetics

  2004cites this paper
• Overexpression of CYP2D6 attenuates the toxicity of MPP+ in actively dividing and differentiated PC12 cells.

  2003cites this paper
• Role of Intestinal Cytochromes P450 in Drug Disposition

  2003cites this paper
• Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry

  2003cites this paper
• The Relative Contribution of Monoamine Oxidase and Cytochrome P450 Isozymes to the Metabolic Deamination of the Trace Amine Tryptamine

  2003influential citation
• Changes in the Murine Nigrostriatal Pathway Following Pyrethroid and Organophosphate Insecticide Exposure: An Immunohistochemical Study

  2002cites this paper
• Dopamine in the CNS II

  2002cites this paper
• Summary of information on human CYP enzymes: human P450 metabolism data

  2002cites this paper
• Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics

  2002influential citation
• Expression, Purification, Biochemical Characterization, and Comparative Function of Human Cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 Allelic Isoforms

  2002cites this paper
• The genetic basis of Parkinson's disease

  2002cites this paper
• Molecular and Cellular Events Regulating Dopamine Neuron Survival

  2002cites this paper
• The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes.

  2002cites this paper
• Accumulation of the 1-methyl-4-phenylpyridinium ion in suncus (Suncus murinus) brain: implication for flavin-containing monooxygenase activity in brain microvessels.

  2001cites this paper
• Cell membrane transport of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the liver and systemic bioavailability.

  2001cites this paper
• CYP2D6 polymorphism in Parkinson's disease: The Rotterdam study

  2001cites this paper
• In Situ Hybridization to Localize mRNAs.

  2001cites this paper
• Characterization and localization of cytochrome P450 mediated metabolism of MPTP to nor-MPTP in mouse brain: Relevance to Parkinson’s disease

  2001cites this paper
• Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain.

  2001cites this paper
• Parkinson’s disease, CYP2D6 polymorphism, and age

  2001cites this paper
• CYP2D6*4 polymorphism is not associated with Parkinson's disease and has no protective role against Alzheimer's disease in the Korean population

  2001cites this paper